SMTL ID : 7voe.1

Crystal structure of 5-HT2AR in complex with aripiprazole

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.90 Å

Oligo State

monomer

Ligands

3 x CLR: CHOLESTEROL(Non-covalent)

CLR.1: 6 residues within 4Å: Chain A: A.24, I.27, L.28, M.31, Y.367, Y.372 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:I.27, A:I.27, A:L.28 Hydrogen bonds: A:Y.372, A:Y.372 CLR.6: 4 residues within 4Å: Chain A: I.30, S.34, L.56 Ligands: OLC.5 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:I.30, A:L.56 Hydrogen bonds: A:S.34 CLR.8: 7 residues within 4Å: Chain A: T.315, M.318, C.326, N.327, V.330, I.331, L.334 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:T.315, A:V.330, A:I.331

1 x 1PE: PENTAETHYLENE GLYCOL(Non-functional Binders)

1PE.2: 6 residues within 4Å: Chain A: W.206, N.210, K.274, N.278, I.281, Q.282 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:K.274

4 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)

OLC.3: 15 residues within 4Å: Chain A: V.90, I.140, P.143, I.144, F.147, K.154, F.168, V.169, I.171, G.172, S.173, S.176, F.177, N.316 Ligands: 9SC.9 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:I.144, A:F.147, A:F.147, A:F.168, A:F.168, A:F.168, A:I.171 Hydrogen bonds: A:S.173, A:S.176, A:N.316 OLC.4: 6 residues within 4Å: Chain A: P.78, S.79, K.80, L.81, V.84, L.149 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:P.78, A:L.81, A:V.84, A:L.149 Hydrogen bonds: A:S.79, A:K.80 OLC.5: 6 residues within 4Å: Chain A: M.48, Y.87, L.91, F.127, W.134 Ligands: CLR.6 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:F.127, A:W.134 Hydrogen bonds: A:Y.87 OLC.7: 7 residues within 4Å: Chain A: K.8, S.11, T.15, Y.73, N.336, V.337, W.340 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:T.15, A:Y.73, A:V.337, A:W.340

1 x 9SC: 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one(Non-covalent)

9SC.9: 17 residues within 4Å: Chain A: W.85, D.89, V.90, S.93, C.161, L.162, F.177, L.181, F.305, V.306, W.309, C.310, F.312, F.313, N.336, V.339 Ligands: OLC.3 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:W.85, A:L.162, A:F.177, A:F.177, A:L.181, A:F.305, A:W.309, A:W.309, A:F.312, A:F.313 Salt bridges: A:D.89

1 x MG: MAGNESIUM ION(Non-covalent)

MG.10: 2 residues within 4Å: Chain A: E.207, D.211 4 PLIP interactions: 4 interactions with chain A Metal complexes: A:E.207, A:E.207, A:D.211, A:D.211

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Chen, Z. et al., Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. Nat.Neurosci. (2022)

Release Date

2021-12-22

Peptides

5-hydroxytryptamine receptor 2A,Soluble cytochrome b562: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Membrane

We predict this structure to be a membrane protein.
Show / Hide

5-hydroxytryptamine receptor 2A,Soluble cytochrome b562

Related Entries With Identical Sequence